Neoatricon (Dopamine Hydrochloride)

Dopamine acts on dopamine (D1), beta‑1, and alpha receptors in a dose‑dependent manner. Low doses cause renal vasodilation via D1 receptors, moderate doses stimulate beta‑1 receptors to raise heart rate and contractility, and high doses activate alpha receptors, producing vasoconstriction and raising systemic vascular resistance.

The dose of Neoatricon is individualized and determined by the prescribing clinician based on the patient’s hemodynamic status, weight, and therapeutic goals. Dosing is typically expressed in micrograms per kilogram per minute and adjusted according to continuous monitoring of blood pressure and cardiac output.

Limited clinical data exist for dopamine use in pregnancy and lactation. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Neoatricon, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Compared with norepinephrine, dopamine offers dose‑dependent renal vasodilation at low doses, which norepinephrine lacks. However, norepinephrine provides more predictable vasoconstriction with fewer tachyarrhythmic effects at equivalent pressor doses. Choice of agent depends on the clinical scenario and physician preference.

Neoatricon must be stored refrigerated between 2 °C and 8 °C, protected from light, and never frozen. Prior to use, inspect the vial for particulate matter and ensure the solution is at room temperature; do not shake vigorously, and use aseptic technique for dilution and administration.

Neoatricon is given by intravenous infusion. The sterile solution is diluted in compatible IV fluids and infused at a rate calculated in micrograms per kilogram per minute. Continuous hemodynamic monitoring is required to titrate the infusion to the desired blood pressure and cardiac output targets.

Serious risks include life‑threatening arrhythmias, myocardial ischemia, severe hypertension, and tissue necrosis at the infusion site. Immediate medical attention is required if patients develop chest pain, irregular heart rhythms, sudden blood pressure spikes, or signs of local tissue damage.

Neoatricon is contraindicated in patients with known hypersensitivity to dopamine or any formulation components, and should be used with extreme caution in individuals with pheochromocytoma, uncorrected tachyarrhythmias, or severe peripheral vascular disease where vasoconstriction could worsen tissue perfusion.